[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dupuytren-disease-of-finger\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dupuytren-disease-of-finger":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643111","phase-1-safety-and-efficacy-study-of-collagenase-cnt201-injection-for-treatment-of-dupuytrens-contracture-100643111",false,"NCT07640425","Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture","A Phase 1\u002F2, Multicenter, Dose Escalating, Dose Expanding, Adaptive Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of Collagenase CNT201 in Adult Participants With Dupuytren's Contracture","Inclusion Criteria:\n\n* Men and women, 18 to 75 years of age, inclusive.\n* Participants with a diagnosis of DC, with a fixed flexion deformity of at least 1 finger, other than the thumb, that have a contracture at least 20°, but not greater than 100°, for MP (not greater than 80° for PIP) joints, caused by a palpable cord.\n* Participants who have a positive Table Top Test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a tabletop.\n* Participants who are naive to CNT201 treatment.\n* Participants who are judged to be in good health, based upon the results of a medical history, physical examination, and safety laboratory profile.\n* Participants who are willing to voluntarily sign and date the Informed Consent Form (ICF) approved by the Institutional Review Board\u002FIndependent Ethics Committee (IRB\u002FIEC).\n\nExclusion Criteria:\n\n* Participants previously exposed to collagenase Clostridium histolyticum for treatment of Dupuytren's disease (Xiaflex, Xiapex®).\n* Participants who have received other treatments for advanced Dupuytren's disease, including surgery (fasciectomy or fasciotomy), needle aponeurotomy\u002Ffasciotomy, or injection of verapamil and\u002For interferon on the selected primary joint within 90 days before the first dose of study treatment.\n* Participants with a chronic muscular, neurological, or neuromuscular disorder that affects the hands, or other medical condition which in the Investigator's opinion will make the participant unsuitable for enrollment in the study.\n* Participants who have a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition (eg, testing positive for tuberculosis \\[TB\\] or Coronavirus disease 2019 \\[COVID-19\\], etc), or history of alcoholism or drug abuse, which in the Investigator's opinion, would make the participant unsuitable for enrollment in the study.\n* Participants who have a known allergic response to collagenase or any other excipient of CNT201 or Xiaflex.\n* Participants who have received a doxycycline or tetracycline derivative within 14 days before the beginning of the study (tetracycline derivatives may inhibit the collagenolytic activity of mammalian collagenase homologs).\n* Participants who have received an anticoagulant (except aspirin ≤150 mg\u002Fday) within 7 days before the start of the study.\n* Female participants who are nursing or pregnant, or plan to become pregnant during the study treatment stage of the study.\n* Participants who have been treated with any investigational drug within 30 days of first dose of study treatment.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This trial is a multicenter, Phase 1\u002F2, study to assess the safety, tolerability, efficacy, PK, and immunogenicity of CNT201 in adult participants with DC (Dupuytren's Contracture).",[28,29],"Dupuytren Contracture","Dupuytren Disease of Finger",[31,32,33],"collagenase injection","CCH","CNT201","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2024-07-23",{"date":42,"type":21},"2027-07-25",{"name":44,"class":45},"CONNEXT","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100371894","post-contracture-release-radiation-for-dupuytrens-disease-100371894","NCT04122313","Post-contracture Release Radiation for Dupuytren's Disease","Efficacy of Post-contracture Release Radiation for the Treatment of Dupuytren's Disease","Inclusion Criteria:\n\n* Diagnoses of Dupuytren's disease\n* English-speaking\n\nExclusion Criteria:\n\n\\- Patients with Dupuytren's disease who are not currently seeking treatment",{"count":55,"type":21},50,"OBSERVATIONAL","To determine if the clinical impression of clinicians, ie that patients are improving with the current treatment pathway for Dupuytren's (contracture release followed by radiation), can be substantiated with scientific evidence.",[59,28,60,29,61,62,63,64,65,66,67],"Dupuytren's Disease","Dupuytren Disease of Palm and Finger","Dupuytrens Contracture of Both Hands","Dupuytren's Disease of Palm of Right Hand","Dupuytren's Disease of Palm of Left Hand","Dupuytren Contracture of Right Palm","Dupuytren Contracture of Left Palm","Dupuytren's Contracture Left","Dupuytren's Contracture Right","2026-03-16",{"date":70,"type":38},"2026-03-19",{"date":72,"type":38},"2019-05-31",{"date":74,"type":21},"2029-03-01",{"name":76,"class":77},"University of Minnesota","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100346972","effectiveness-of-percutaneous-needle-aponeurotomy-100346972","NCT03797690","Effectiveness of Percutaneous Needle Aponeurotomy","Effectiveness of Percutaneous Needle Aponeurotomy for Dupuytren's Disease: a Multicenter, Randomised, Non-inferiority Trial, With Surgery as Comparator","EFAPAD","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Ascertained Dupuytren disease: palpable fibrotic nodule or cord developed from the palmar aponeurosis, flexion contracture of a metacarpophalangeal or proximal interphalangeal joint.\n* Presence of at least one flexion contracture of a metacarpophalangeal joint of the hand due to Dupuytren's disease and \\> or = 20°\n* Written informed consent signed by the patient\n* Patient affiliated to the social security\n\nExclusion Criteria:\n\n* Presence of other musculoskeletal disorders of the hand than Dupuytren's disease: known inflammatory rheumatic disease of the hand, clinical signs of inflammatory rheumatic disease of the hand, MP or PIP pain at inclusion visit.\n* Previous surgery of the hand to be treated resulting in functional limitation or limitation of finger mobility\n* Any other pathological condition or limited range of motion in the finger to be treated\n* Psychiatric status precluding patient evaluation; vulnerable persons; adults under legal protection order or incompetent, physically or mentally incapable of giving his consent.\n* Pregnant or beastfeeding women\n* Participation in another interventional trial",{"count":87,"type":21},120,[89],"NA","The main objective is to investigate if percutaneous needle aponeurotomy is non-inferior to open surgery using aponeurectomy in treatment of flexion contracture due to Dupuytren's disease.\n\nOur hypothesis is that percutaneous needle aponeurotomy has suitable efficacy and safety profile for large application in the treatment of Dupuytren's disease and that it is consequently able to drastically reduce the need of open surgery in this indication.",[29],[93,94,95,96],"Dupuytren's disease","Percutaneous needle aponeurotomy","Limited aponeurectomy","Randomized trial","2025-04-01",{"date":99,"type":38},"2025-04-02",{"date":101,"type":38},"2020-11-02",{"date":103,"type":21},"2029-02-14",{"name":105,"class":77},"Assistance Publique - Hôpitaux de Paris",4]